Bicara Therapeutics posts ASCO presentation on ficerafusp alfa plus pembrolizumab in HPV-negative head and neck cancer

Bicara Therapeutics Inc.

Bicara Therapeutics Inc.

BCAX

0.00
  • Bicara Therapeutics published an ASCO poster on ficerafusp alfa with pembrolizumab in first-line R/M HPV-negative HNSCC with PD-L1 CPS ≥1.
  • Pooled analysis linked deep response (≥80% tumor shrinkage) to longer DOR, PFS, OS versus PR <80%.
  • Median DOR 31.6 months for deep response versus 8.2 months for PR <80%; hazard ratio 0.31 (95% CI 0.11-0.84).
  • Median PFS 36.9 months versus 10.9 months; hazard ratio 0.35 (95% CI 0.15-0.91).
  • Median OS not reached versus 33.6 months; hazard ratio 0.37 (95% CI 0.13-1.10).


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief on May 30, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.